RGNX REGENXBIO Inc.
REGENXBIO Inc. (RGNX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 22% planned / 78% discretionary
Largest single sale: $472.3K.
Where they traded
Last open-market purchase: August 27, 2026 , by Ciongoli Gregory Austin .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director | Buy | 53,407 | $9.36 | $499.7K | 118,035 | |
| Ciongoli Gregory Austin | Director | Buy | 49,196 | $9.14 | $449.7K | 64,628 | |
| PAKOLA STEVE | Chief Medical Officer | Sell 10b5-1 | 2,161 | $13.64 | $29.5K | 213,009 −1% of holding | |
| PAKOLA STEVE | Chief Medical Officer | Sell | 36,725 | $12.86 | $472.3K | 213,009 −14.7% of holding | |
| PAKOLA STEVE | Chief Medical Officer | Sell | 19,608 | $11.04 | $216.5K | 213,009 −8.4% of holding | |
| PAKOLA STEVE | Chief Medical Officer | Sell 10b5-1 | 15,309 | $11.02 | $168.7K | 232,617 −6.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.